稀有血型系统在重症新型冠状病毒肺炎风险判定中的应用价值
The Usefulness of Rare Blood Group Systems in the Risk Determination for Severe COVID-19.
作者信息
Konstantinidis Theocharis G, Iliadi Valeria, Martinis Georges, Panopoulou Maria
机构信息
Blood Transfusion Center, University General Hospital of Alexandroupolis Dragana Campus, 68100 Alexandroupolis, Greece.
Laboratory of Microbiology, Democritus University of Thrace, University General Hospital of Alexandroupolis Dragana Campus, 68100 Alexandroupolis, Greece.
出版信息
Pathophysiology. 2021 Nov 3;28(4):496-500. doi: 10.3390/pathophysiology28040032.
The newly identified human coronavirus was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), based on a detailed analysis of clinical manifestation. It was reported that blood type O individuals were less likely to become infected by SARS-CoV, while blood type A individuals have an increased risk of severe illness. The Forssman antigen, or Forssman glycolipid synthase (FS), was first described in 1911 by John Frederick Forssman. Blood type A/B glycosyltransferases (AT/BTs) and Forssman glycolipid synthase (FS) are encoded by the evolutionarily related ABO (A/B alleles) and genes. In this article, based on published studies about the pathogenesis of the COVID-19, we hypothesize the possible relationship between the COVID-19 infection and rare blood type systems, such as the Forssman antigen system.
根据对临床表现的详细分析，新发现的人类冠状病毒被命名为严重急性呼吸综合征冠状病毒2（SARS-CoV-2）。据报道，O型血个体感染SARS-CoV的可能性较小，而A型血个体患重病的风险增加。福斯曼抗原或福斯曼糖脂合酶（FS）于1911年由约翰·弗雷德里克·福斯曼首次描述。A型/ B型血糖基转移酶（AT/BTs）和福斯曼糖脂合酶（FS）由进化相关的ABO（A/B等位基因）和基因编码。在本文中，基于已发表的关于COVID-19发病机制的研究，我们推测了COVID-19感染与罕见血型系统（如福斯曼抗原系统）之间的可能关系。
Zotero 插件